Type 1 Diabetes: Causes, Insulin Therapy, Blood Sugar Targets, and Long-Term Management

What Exactly Is Type 1 Diabetes?

Type 1 diabetes is an autoimmune disease, not a lifestyle disease. The immune system mistakenly attacks and kills the insulin-producing beta cells in the islets of Langerhans inside the pancreas. Without those cells, the body cannot produce any meaningful amount of insulin, and blood glucose rises to dangerous levels within hours to days of total beta-cell loss.

The condition accounts for approximately 5 to 10% of all diabetes diagnoses worldwide, according to the American Diabetes Association [1]. Peak onset occurs in childhood and adolescence, but roughly 40% of new type 1 cases are diagnosed in adults over 30, a presentation sometimes called latent autoimmune diabetes in adults (LADA) [2].

Genetic risk is real but incomplete. Carrying the HLA-DR3 or HLA-DR4 alleles raises lifetime risk substantially, yet the majority of people with these alleles never develop the disease [3]. Environmental triggers, including enterovirus infections and early gut microbiome disruption, are under active investigation as the factors that convert genetic susceptibility into overt autoimmunity [4].

The distinction from type 2 diabetes matters clinically. In type 2 diabetes, beta cells still function but produce insufficient insulin relative to the body's needs, and peripheral insulin resistance compounds the problem. In type 1 diabetes, beta-cell function is effectively zero. That difference determines every treatment decision.

How Insulin Regulates Blood Sugar

Insulin is the only hormone that lowers blood glucose. After a meal, rising glucose in the portal circulation signals pancreatic beta cells to secrete insulin in two phases: a rapid first-phase spike within 2 to 5 minutes, then a sustained second phase over 60 to 120 minutes [5]. Insulin binds to receptors on muscle, fat, and liver cells, opening glucose transporters (primarily GLUT4) and suppressing hepatic glucose output.

When beta cells are destroyed, both phases disappear. Blood glucose after meals can exceed 250 mg/dL within an hour, and between meals the liver releases glucose unchecked, causing fasting hyperglycemia that compounds overnight [6].

The kidney begins spilling glucose into urine (glycosuria) when blood glucose exceeds roughly 180 mg/dL. That osmotic effect pulls water out of cells and drives the classic symptoms: polyuria (excessive urination), polydipsia (intense thirst), and unexplained weight loss despite normal or increased eating.

Without insulin replacement, the body cannot use glucose for energy and shifts entirely to fat breakdown. This produces ketone bodies at a rate that overwhelms buffering systems, causing diabetic ketoacidosis (DKA), a medical emergency with a case fatality rate of approximately 0.2 to 0.3% even in modern intensive care settings [7].

Diagnosing Type 1 Diabetes: Tests and Thresholds

Diagnosis uses standard glycemic criteria, then autoantibody testing to confirm the autoimmune subtype. The 2024 ADA Standards of Care define diabetes as any one of the following [1]:

• Fasting plasma glucose at or above 126 mg/dL on two separate occasions
• 2-hour plasma glucose at or above 200 mg/dL during a 75-gram oral glucose tolerance test
• HbA1c at or above 6.5% confirmed on repeat testing
• Random plasma glucose at or above 200 mg/dL with classic symptoms (only one test needed)

Prediabetes, by contrast, is defined as fasting glucose between 100 and 125 mg/dL, or HbA1c between 5.7% and 6.4% [1]. People with prediabetes do not have type 1 diabetes, but the overlap is worth understanding: some adults first labeled as prediabetic and later typed as LADA had undetected autoimmunity all along.

Autoantibody panels seal the type 1 diagnosis. The five most clinically used markers are islet cell antibodies (ICA), anti-glutamic acid decarboxylase (anti-GAD65), insulin autoantibodies (IAA), islet antigen-2 antibodies (IA-2A), and zinc transporter 8 antibodies (ZnT8A). Roughly 98% of newly diagnosed type 1 patients test positive for at least one [8]. C-peptide levels below 0.2 nmol/L confirm minimal residual beta-cell function and further distinguish type 1 from type 2 diabetes.

Gestational diabetes uses different thresholds. The American College of Obstetricians and Gynecologists recommends screening all pregnant patients between 24 and 28 weeks of gestation using a 50-gram glucose challenge test, with confirmatory 3-hour 100-gram testing if the 1-hour result reaches or exceeds 140 mg/dL [9]. Gestational diabetes is driven primarily by placental hormones causing insulin resistance, not autoimmunity, and it resolves after delivery in most cases. However, women who had gestational diabetes carry a 35 to 60% lifetime risk of developing type 2 diabetes [10].

Insulin Therapy: Types, Doses, and Regimens

Every person with type 1 diabetes requires insulin. Full stop. The standard of care is a basal-bolus regimen: a long-acting (basal) insulin to suppress overnight hepatic glucose output, combined with rapid-acting (bolus) insulin timed to meals and corrective doses.

Basal insulins include insulin glargine U-100 (Lantus), glargine U-300 (Toujeo), insulin detemir (Levemir), and insulin degludec U-200 (Tresiba). Degludec has the longest duration, up to 42 hours, and produces fewer nocturnal hypoglycemic events compared with glargine in head-to-head trials [11].

Rapid-acting analogs include insulin lispro (Humalog), insulin aspart (NovoLog), and insulin glulisine (Apidra). Faster-acting formulations, insulin aspart faster (Fiasp) and inhaled insulin (Afrezza), reduce post-meal glucose spikes more aggressively but require careful timing [12].

A typical starting total daily dose for type 1 is 0.4 to 0.5 units per kilogram of body weight per day, split roughly 50% basal and 50% bolus, though individual requirements vary widely based on activity, diet, stress, and residual beta-cell function [1].

The HealthRX Insulin Selection Framework for type 1 diabetes considers four variables before recommending a regimen: (1) CGM access and patient comfort with data interpretation, (2) hypoglycemia awareness (intact or impaired), (3) willingness to use an insulin pump versus multiple daily injections, and (4) insurance formulary tier for each analog. Patients with hypoglycemia unawareness receive degludec or pump therapy first due to the reduced hypoglycemia risk profile, before titrating toward tighter HbA1c goals.

Pump therapy (continuous subcutaneous insulin infusion, CSII) delivers rapid-acting insulin around the clock through a subcutaneous catheter, eliminating the need for daily basal injections. The REPOSE trial (N=267) found that pump therapy did not significantly outperform multiple daily injections on HbA1c at 2 years (7.4% vs. 7.5%), but patient-reported quality of life was meaningfully better in the pump group [13].

Hybrid closed-loop systems pair a pump with a CGM and an algorithm that adjusts basal delivery in real time. The MiniMed 780G system achieved a mean time-in-range (70 to 180 mg/dL) of 74% in the ADAPT trial, compared with 64% for sensor-augmented pump therapy alone [14]. The Omnipod 5 system produced similar results in its key trial, with time-in-range of 73.9% and a mean HbA1c of 7.0% across all age groups studied [15].

Blood Sugar Targets: What Numbers Actually Matter

The 2024 ADA Standards of Care set the following glycemic targets for most non-pregnant adults with type 1 diabetes [1]:

• HbA1c: below 7.0%
• Preprandial glucose: 80 to 130 mg/dL
• Peak postprandial glucose (1 to 2 hours after meal start): below 180 mg/dL
• Time-in-range (CGM): above 70%
• Time below range (<70 mg/dL): below 4%
• Time below range (<54 mg/dL): below 1%

The ADA guideline statement reads: "For many adults with type 1 or type 2 diabetes, an A1C goal of less than 7% (53 mmol/mol) is appropriate without significant hypoglycemia" [1]. Tighter targets, such as below 6.5%, may suit younger patients with short disease duration and no hypoglycemia unawareness, but they carry higher hypoglycemia risk.

HbA1c reflects average glucose over approximately 90 days but misses glycemic variability. Two patients can share an identical HbA1c of 7.0% while one spends 30% of the day hypoglycemic and the other maintains steady glucose. CGM-derived time-in-range captures that variability and is now considered a co-primary endpoint alongside HbA1c in type 1 diabetes management.

The DCCT (Diabetes Control and Complications Trial, N=1,441) remains the defining evidence base. Intensive insulin therapy targeting HbA1c below 7% reduced the risk of retinopathy progression by 76%, nephropathy by 50%, and neuropathy by 60% compared with conventional therapy over 6.5 years [16]. The EDIC follow-up study, now running for more than 30 years, confirmed that the benefits of early tight control persist for decades, a phenomenon called "metabolic memory" [17].

Insulin Resistance in Type 1 Diabetes

Insulin resistance is not exclusive to type 2 diabetes. Many adults with type 1 diabetes develop clinically significant insulin resistance, particularly those who are overweight, sedentary, or have been on high insulin doses for years. This overlap is sometimes called "double diabetes."

A 2016 analysis of the T1D Exchange registry (N=25,529) found that 44% of adults with type 1 diabetes had a body mass index above 25 kg/m², and those with higher BMI required substantially higher insulin doses to achieve equivalent glycemic control [18]. Higher total daily insulin doses correlate with increased cardiovascular risk independent of HbA1c, which may explain why cardiovascular disease remains the leading cause of death in type 1 diabetes even among patients with well-controlled glucose.

Adjunctive agents that reduce insulin resistance have generated interest. Metformin added to insulin in the REMOVAL trial (N=428 to 3 years) did not significantly improve HbA1c but reduced total insulin dose by roughly 2 units per day and lowered LDL cholesterol [19]. SGLT-2 inhibitors (dapagliflozin, empagliflozin) added to insulin reduce HbA1c by 0.4 to 0.6% and body weight by 2 to 3 kg in type 1 trials, though they carry a 2 to 4-fold increased risk of DKA and carry only off-label status in the United States for type 1 diabetes [20].

Complications: Microvascular and Macrovascular Risks

Chronic hyperglycemia damages blood vessels through four primary mechanisms: advanced glycation end-product accumulation, oxidative stress, polyol pathway activation, and protein kinase C activation [21]. The resulting damage affects small vessels (microvascular) and large vessels (macrovascular) differently.

Microvascular complications include diabetic retinopathy, nephropathy, and peripheral neuropathy. Retinopathy affects roughly 27% of people with type 1 diabetes after 5 years and nearly 98% after 15 years of disease [22]. Nephropathy progresses to end-stage renal disease in approximately 30% of type 1 patients over a lifetime without intensive management. Annual screening with urine albumin-to-creatinine ratio and estimated glomerular filtration rate is recommended starting 5 years after diagnosis in adults and immediately at diagnosis in children.

Macrovascular complications (coronary artery disease, stroke, peripheral artery disease) account for roughly 50% of deaths in type 1 diabetes. People with type 1 diabetes have a 10-fold higher risk of cardiovascular death compared with age-matched non-diabetic controls [23]. Statin therapy is recommended for adults with type 1 diabetes over 40 and for those under 40 with additional cardiovascular risk factors, per 2024 ADA guidelines [1].

Teplizumab: The First Drug to Delay Type 1 Onset

In November 2022 the FDA approved teplizumab (Tzield), an anti-CD3 monoclonal antibody, making it the first drug to delay the onset of clinical type 1 diabetes in high-risk individuals [24]. The key trial (N=76) showed that a 14-day course of teplizumab delayed the median time to type 1 diagnosis by 2 years compared with placebo (P<0.001) in relatives of people with type 1 diabetes who had two or more autoantibodies and dysglycemia but had not yet crossed diagnostic thresholds [25].

Teplizumab works by modulating CD8-positive T cells, slowing the autoimmune attack on remaining beta cells. The drug does not cure type 1 diabetes or eliminate the eventual need for insulin. Screening high-risk relatives with autoantibody panels is now a practical clinical step, since identifying stage 2 type 1 diabetes (two or more autoantibodies plus dysglycemia) makes someone a candidate for teplizumab.

Prediabetes, Type 2 Diabetes, and How They Differ From Type 1

Understanding the full spectrum of glucose disorders helps clarify why type 1 treatment cannot be applied to these other conditions, and vice versa.

Prediabetes (HbA1c 5.7 to 6.4%, fasting glucose 100 to 125 mg/dL) represents a state of progressive beta-cell failure and worsening insulin resistance before glucose meets diagnostic thresholds for diabetes. The Diabetes Prevention Program (DPP, N=3,234) showed that intensive lifestyle intervention (7% weight loss, 150 minutes of moderate exercise per week) reduced progression to type 2 diabetes by 58% over 2.8 years, while metformin 850 mg twice daily reduced progression by 31% [26]. Lifestyle beats metformin. Neither intervention applies to type 1 prevention.

Type 2 diabetes involves a combination of beta-cell dysfunction and peripheral insulin resistance. It affects an estimated 37.3 million Americans (11.3% of the population) [1], vastly outnumbering type 1. GLP-1 receptor agonists (semaglutide, liraglutide, tirzepatide) have transformed type 2 management. In STEP-1 (N=1,961), semaglutide 2.4 mg produced 14.9% mean weight loss at 68 weeks versus 2.4% with placebo [27]. These agents improve insulin sensitivity and reduce cardiovascular events but have no meaningful role in type 1 diabetes management at present.

Gestational diabetes is diagnosed and managed during pregnancy, as described above. After delivery, women should be retested at 6 to 12 weeks postpartum with a 75-gram OGTT, and then every 1 to 3 years thereafter, given the high lifetime risk of progressing to type 2 diabetes [9].

Lifestyle Factors That Affect Blood Sugar in Type 1 Diabetes

Insulin doses cover meals and correct highs, but lifestyle variables change insulin requirements substantially and are often underappreciated.

Exercise lowers blood glucose during and after aerobic activity by increasing GLUT4 translocation independent of insulin. Resistance training and high-intensity interval training can transiently raise glucose through catecholamine release before it falls [28]. The practical implication: aerobic exercise typically requires a 20 to 30% bolus reduction or a carbohydrate supplement of 15 to 30 grams per 30 minutes of moderate activity. Guidelines from the American Diabetes Association recommend pre-exercise glucose of 126 to 180 mg/dL as the safer target range before starting [1].

Sleep deprivation raises cortisol and growth hormone, both of which oppose insulin action and raise fasting glucose. A single night of 4 hours of sleep increases insulin requirements the following day by approximately 20 to 25% in type 1 patients, based on controlled inpatient studies [29].

Psychological stress activates the hypothalamic-pituitary-adrenal axis, releasing cortisol and adrenaline. Both hormones stimulate hepatic glucose output and impair insulin signaling. Stress management, including cognitive behavioral therapy and mindfulness-based interventions, has been shown to reduce HbA1c by 0.3 to 0.5% over 6 months in people with diabetes [30].